ClinicalTrials.gg
CompletedNCT06067490Updated Dec 2, 2024

A Phase I Study of RC1416 Injection

A Phase 1 interventional study of RC1416(SAD) and Placebo(SAD) in Healthy Volunteers, sponsored by Nanjing RegeneCore Biotech Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-02.

Sponsored by Nanjing RegeneCore Biotech Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was May 2024, 2 years 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

This is a phase I study to evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of RC1416 injection via Subcutaneous Administration in Healthy Adult Volunteers.

Read the detailed description

RC1416 is a bispecific homodimer nanobody .It is being developed by Nanjing RegeneCore Biotech Co., Ltd. as a potential therapy for asthma. A total 48 healthy adult subjects will be enrolled in six groups to access the safety and tolerability of single subcutaneous injection of RC1416 in healthy adult subjects.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Nanjing RegeneCore Biotech Co., Ltd. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 to 50 years(including the boundary value),Chinese.
  • Male Weight of 50 kg to 90 kg,femal weight of 40kg to 90kg, and of 19.0 to 28.0 kg/m2 (including the boundary value).
  • Subject have no fertility, sperm/egg donation plan for at least 6 months from the signing of the to the end of the treatment, and voluntarily takes medically recognized effective non-drug measures (including his partner) during the trial.

Exclusion criteria

Exclusion Criteria:

  • Have participated in clinical trials of drugs in other trials within 3 months prior to screening .
  • With investigator-identified abnormalities of the cardiovascular, respiratory, digestive, endocrine systems (e.g., diabetes), nervous/mental systems, blood, and lymphatic systems (immune deficiency), and musculoskeletal systems.
  • With clinically significant infectious disease (e.g., cellulitis, abscess, or systemic infection (e.g., sepsis), or history of clinically significant opportunistic infection (e.g.,invasive candidiasis or pneumocystis pneumonia) within 3 months before to screening.
  • With a history of active tuberculosis or the presence of latent tuberculosis infection or active tuberculosis indicated by any current symptoms, signs or laboratory tests.
  • Have an allergic constitution, history of allergy to the test drug ingredient or to any drug or food or pollen.
  • Received chemotherapy, radiotherapy, therapy, or high-dose treatment within 5 years before signing the .
  • Use of any prescription, OTC, traditional Chinese medicine, vitamin or health product within 1 month prior to screening;
  • Received live or attenuated vaccines within 1 month or have any vaccination schedule during the clinical trial.
  • Had surgery within 6 months prior to screening or planned surgery during the trial.
  • Have difficulty with venous blood collection, or subjects who faint at the sight of blood or a needle, or have difficulty with subcutaneous administration.
  • Have lost or donated blood for more than 400 mL(not including menstrual blood loss )or received blood transfusion or using blood products within 3 months before signing informed consent or planning to donate blood during the study or within 1 month after the trial.
  • Excessive consumption of tea, coffee or caffeinated beverages (more than 8 cups per day, 250 mL per cup) within 6 months prior to screening.
  • Have consumed any beverage or food containing grapefruit or caffeine (such as grapefruit juice, coffee, strong tea, chocolate, caffeinated carbonated beverages, cola, cocoa, etc.) in the 48 hours prior to screening.
  • Have special dietary requirements and cannot comply with a unified diet.
  • Smoked ≥5 cigarettes per day within 3 months prior to screening or or could not guarantee to quit smoking during the trial.
  • Regularly drank alcohol within 6 months prior to screening(i.e., more than 14 standard units per week for women and more than 21 standard units per week for men (1 standard unit containing 14g of alcohol, such as 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine) or could not abstinence during the trial; Or a positive alcohol breath test;
  • With previous history of drug abuse/drug use; Or test positive for drug abuse screening (including THC, morphine, ketamine, methamphetamine, benzodiazepines, cocaine);
  • Pregnant or lactating women, or positive blood pregnancy test results;
  • Positive for surface antigen (HBsAg), virus antibody (anti-HCV), (HIV) antigen-antibody combined detection, syphilis treponema specific antibody at the screening visit.
  • Subjects with the results of physical examination, vital signs, laboratory examination and other auxiliary examinations (chest imaging, abdominal B-ultrasonography, 12-lead , etc.) were judged by the investigator as abnormal and clinically significant during the screening period.
  • The investigators considered that subjects were not suitable for this clinical trial for other reasons.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    RC1416

    RC1416(SAD),single ascending (25mg-600mg) of RC1416 by subcutaneous injection

    Drug: RC1416(SAD)

  • Placebo comparator
    Placebo

    Placebo(SAD), Each subjects will receive the placebo once by subcutaneous injection.

    Drug: Placebo(SAD)

Interventions

  • RC1416(SAD),there are six doses(25mg-600mg) in this part. Each subjects will receive the drug once by subcutaneous injection.

    Also known as: RC1416

  • DrugPlacebo(SAD)

    Placebo(SAD), Each subjects will receive the placebo once by subcutaneous injection.

    Also known as: RC1416 Placebo

06

What researchers measure

Primary outcomes

  1. Adverse Events

    incidence ,severity and relation to investigational drugs of Adverse Events according to CTCAE V5.0

    Time frame: up to 92 days

  2. Vital Signs

    number of praticipants with clinically notable Vital Signs according to CTCAE V5.0

    Time frame: up to 92 days

  3. Laboratory Tests

    number of praticipants with clinically notable Laboratory Tests according to CTCAE V5.0

    Time frame: up to 92 days

  4. ECG

    number of praticipants with clinically notable Electrocardiogram(ECG) Values according to CTCAE V5.0

    Time frame: up to 92 days

  5. Injection Site Reaction

    number of praticipants with clinically notable Injection Site Reaction according to CTCAE V5.0

    Time frame: up to 4 days

Secondary outcomes

  1. Pharmacokinetics-Cmax

    maximum serum concentration

    Time frame: up to 92 days

  2. Pharmacokinetics-AUC 0-t

    area under the concentration-time curve (AUC) from administration to the last measurable concentration

    Time frame: up to 92 days

  3. Pharmacokinetics-AUC 0-inf

    AUC extrapolated to infinitymeasurable concentration

    Time frame: up to 92 days

  4. Anti-Drug antibody (ADA)

    number and percentage of subjects tested ADA positive

    Time frame: up to 92 days

07

Study locations

1 site
  • China-japan Friendship Hospital
    Beijing, Beijing 100029, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2023 to primary completion in May 2024, 10 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2023
First posted
Oct 5, 2023
StartActual
Jun 29, 2023
Primary completionActual
May 14, 2024
CompletionActual
May 14, 2024
Last update
Dec 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06067490
Lead sponsor
Nanjing RegeneCore Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Oct 5, 2023
Start date
Jun 29, 2023
Primary completion
May 14, 2024
Completion
May 14, 2024
Last update
Dec 2, 2024

Study contacts

Li J Tong, Doctor
principal investigator · China-Japan Friendship Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: RC1416

Start the discussion